Xencor, Inc.
XNCRXencor, Inc. (XNCR) is a biotechnology company focused on designing and developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Leveraging its proprietary XmAb technology platform, Xencor aims to create innovative therapies with improved efficacy and safety profiles. The company collaborates with various pharmaceutical partners and conducts research to advance its pipeline of targeted biologics.
Company News
A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations...
The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expa...
Xencor reported strong Q2 2025 financial performance with revenue of $43.6 million, beating estimates by 93%. The company advanced several clinical programs in oncology and autoimmune disorders and received a significant milestone payment from Incyte.
The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.
Xencor shares surged 10.5% after the company announced a secondary stock offering to raise $175 million. The company plans to use the funds to support its pipeline development. However, earnings and revenue expectations for the upcoming quarter are negative, which may impact the stock's future performance.
